CHICAGO--(BUSINESS WIRE)-- Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global ...
Observing the absence of a prescribed procedure under the relevant laws regarding the appointment of members to the Appellate Tribunal Inland Revenue (ATIR), the Islamabad High Court (IHC) has ...
The Islamabad High Court (IHC) has ordered the Ministry of Law and Justice to serve notices on 10 judicial members (BS-21) working on a contract basis in the Appellate Tribunal Inland Revenue, ...
November 11, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation to AVI-4658 for the treatment of Duchenne muscular dystrophy, SQ109 for the treatment of tuberculosis, ...
ISLAMABAD: In a landmark judgment, the Appellate Tribunal, Inland Revenue (ATIR), has outlined the consequences of legislative errors in the substitution of Section 11B of the Sales Tax Act, 1990, ...
IMF lowers growth forecast to 3.5pc Procedural flaw in Rs880m IT case: ATIR recalls order despite reference pending before ...
Kiadis Pharma B.V. announced that the fiveyear follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose ...
AMSTERDAM, The Netherlands, Nov. 6Â -- Kiadis Pharma announced today that its lead product ATIR has been granted orphan drug designation by the US Food and Drug Administration (FDA) as a therapy for ...
The ATir interface was designed to emulate the function of a PC AT keyboard and be controlled by an ATtiny45 microcontroller based IR remote control. The ATir interface was designed to emulate the ...
~ 67% survival demonstrated after 5 years and no transplant related mortalities ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results